<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03796806</url>
  </required_header>
  <id_info>
    <org_study_id>18-002404</org_study_id>
    <nct_id>NCT03796806</nct_id>
  </id_info>
  <brief_title>Methods Validation Assessment for Study of Inflammatory Skin Disease</brief_title>
  <official_title>Methods Validation Assessment for Study of Inflammatory Skin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Assess validity of methods involved in molecular studies of the skin in inflammatory&#xD;
           skin disease&#xD;
&#xD;
        2. Assess feasibility of methods for grafting fresh human skin (normal and diseased with&#xD;
           inflammatory skin disease) onto an established xenograft murine model.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of fixed tissue specimens for research studies is attractive, because a large number&#xD;
      of relevant specimens can be collected quickly from tissue registry. There is a current lack&#xD;
      of knowledge regarding to what extent formalin fixation alters the identification of proteins&#xD;
      in the skin with inflammatory dermatoses. This information would be important to assess when&#xD;
      determining the limitations (or potentially lack thereof) of using fixed specimens in&#xD;
      research.&#xD;
&#xD;
      Collaborators have successfully developed a murine model that can accept human skin&#xD;
      xenografts. While those investigators have successfully demonstrated transplantation of&#xD;
      healthy skin onto mice, it is unknown whether skin affected by inflammatory disease can be&#xD;
      transplanted and, if so, whether the inflammatory skin disease remains, whether it spreads to&#xD;
      involve host skin, or whether it resolves. Determining feasibility of transplanting inflamed&#xD;
      human skin using this model, as well as observing the course of this inflammation, are the&#xD;
      next steps in advancing this potentially invaluable research modality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative analysis of proteomes on fresh versus formalin-fixed-paraffin-embedded tissue.</measure>
    <time_frame>8 months</time_frame>
    <description>Identification and quantification of proteins as obtained by liquid chromatography-mass spectrometry methods using fresh and formalin-fixed-paraffin-embedded tissue. Mass spectrometry data will be matched against a composite protein sequence database using the MyriMatch search engine and IDPicker will filter protein identification at 2% false discovery rate. QuasiTel software will process the spectral count data for the identification of differentially expressed proteins.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viability of human inflammatory skin (lichen planus) graft in a xenograft murine model</measure>
    <time_frame>8 months</time_frame>
    <description>Viability of diseased human graft into an established murine xenograft model by visual inspection and microscopic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of inflammation around human inflammatory skin graft (lichen planus) and elsewhere in a established xenograft murine model</measure>
    <time_frame>8 months</time_frame>
    <description>Assessment of inflammation around graft and elsewhere in the host by visual inspection and microscopic analysis.</description>
  </primary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Lichen Planus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic patients with active lichen planus and residing within a 50-mile radius of Mayo&#xD;
        Clinic-Rochester.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Adults &gt;18 years with active cutaneous lichen planus with capacity to consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent skin infection&#xD;
&#xD;
          -  Wound healing disturbances&#xD;
&#xD;
          -  Patients on systemic immunosuppressive medications.&#xD;
&#xD;
          -  Lidocaine allergy&#xD;
&#xD;
          -  Platelets &lt;10,000&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia S Lehman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2019</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Julia S. Lehman</investigator_full_name>
    <investigator_title>Professor of Dermatology and Laboratory Medicine and Pathology</investigator_title>
  </responsible_party>
  <keyword>lichen planus</keyword>
  <keyword>proteomics</keyword>
  <keyword>xenograft model for lichen planus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

